Background Combinations (combos) of VEGFR-TKI plus anti-PD1/L1 immunotherapy (IO) are the standard of care for first-line therapy of mRCC pts due to increased response rate, prolonged progression-free (PFS) and overall (OS) survivals compared to TKI alone. It is well recognized that the majority of toxicities of the combos are due to the TKI. Methods mRCC pts with prior nephrectomy, and with no symptomatic/bulky disease nor liver mets, were treated with Ave 800 mg flat dose IV Q2W + Axi 5 mg PO BID for 36 weeks (W). At W36, pts who achieved RECIST partial response (PR) discontinued Axi and continued Ave until disease progression (PD) or unacceptable toxicity. In case of PD, they re-started Axi for 24W and discontinued it again in case of new PR while continuing Ave. Pts with stable disease at 36W continued the combo until PD or unacceptable toxicity. Primary endpoint: rate of pts free of progression (FoP) after 8W from Axi discontinuation (≥48%). Secondary endpoints: median PFS, objective response rate (ORR) and safety. 75 pts have been planned to be enrolled. Results 79 pts were enrolled and 75 evaluated for efficacy (IMDC risk: 40.0% favorable, 57.3% intermediate, 2.7% poor). A total of 29 (38.2%) pts discontinued Axi at 36W; the rate of pts FoP after 8W was 72.4%. With a median follow-up of 19.3 mos, the mPFS was 23.8 mos (95%CI, NR-NR) with 70% of pts FoP at 18 mos; mOS was not reached. The ORR was 76.0% (12.0% CR, 64.0% PR); 18.7% had SD and 4.0% had PD. The median duration of first Axi discontinuation was 16.0 weeks (95%CI, 10.9 – 21.1). Among the 29 pts who discontinued Axi, 9 were still ongoing, 20 had PD and 19 restarted Axi (9 ongoing, 6 had further PD, 4 discontinued Axi again). Safety: 96.2% of pts had at least one adverse event (AE) and 40.5% had G3-G4 AEs with no treatment-related death. All-grades and G3-G4 axitinib-related AEs were reported in 34.2% and 11.4% of overall pts, respectively, and in 10.3% and 0% of those who discontinued Axi. Conclusions The TIDE-A study shows that TKI discontinuation is safe for selected mRCC pts with evidence of response to TKI+IO combos in first line. Axi discontinuation allows decreasing of toxicity, while maintaining the possibility of Axi benefit in case of its reintroduction.
1884MO Phase II study of avelumab (Ave) plus intermittent axitinib (Axi) in previously untreated patients (pts) with metastatic renal cell carcinoma (mRCC): The TIDE-A study / Iacovelli, R.; Ciccarese, C.; Bersanelli, M.; Zucali, P. A.; Fantinel, E.; Bimbatti, D.; Verzoni, E.; Accettura, C.; Bonomi, L.; Buttigliero, C.; G. fornarini, Null; Pipitone, S.; Atzori, F.; Masini, C.; Massari, F.; Primi, F.; Buti, S.; Perrino, M. R. A.; Pafumi, S.; Tortora, G.. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - 34:S2(2023), pp. S1013-S1013. [10.1016/j.annonc.2023.09.1114]
1884MO Phase II study of avelumab (Ave) plus intermittent axitinib (Axi) in previously untreated patients (pts) with metastatic renal cell carcinoma (mRCC): The TIDE-A study
Buti, S.Investigation
;
2023-01-01
Abstract
Background Combinations (combos) of VEGFR-TKI plus anti-PD1/L1 immunotherapy (IO) are the standard of care for first-line therapy of mRCC pts due to increased response rate, prolonged progression-free (PFS) and overall (OS) survivals compared to TKI alone. It is well recognized that the majority of toxicities of the combos are due to the TKI. Methods mRCC pts with prior nephrectomy, and with no symptomatic/bulky disease nor liver mets, were treated with Ave 800 mg flat dose IV Q2W + Axi 5 mg PO BID for 36 weeks (W). At W36, pts who achieved RECIST partial response (PR) discontinued Axi and continued Ave until disease progression (PD) or unacceptable toxicity. In case of PD, they re-started Axi for 24W and discontinued it again in case of new PR while continuing Ave. Pts with stable disease at 36W continued the combo until PD or unacceptable toxicity. Primary endpoint: rate of pts free of progression (FoP) after 8W from Axi discontinuation (≥48%). Secondary endpoints: median PFS, objective response rate (ORR) and safety. 75 pts have been planned to be enrolled. Results 79 pts were enrolled and 75 evaluated for efficacy (IMDC risk: 40.0% favorable, 57.3% intermediate, 2.7% poor). A total of 29 (38.2%) pts discontinued Axi at 36W; the rate of pts FoP after 8W was 72.4%. With a median follow-up of 19.3 mos, the mPFS was 23.8 mos (95%CI, NR-NR) with 70% of pts FoP at 18 mos; mOS was not reached. The ORR was 76.0% (12.0% CR, 64.0% PR); 18.7% had SD and 4.0% had PD. The median duration of first Axi discontinuation was 16.0 weeks (95%CI, 10.9 – 21.1). Among the 29 pts who discontinued Axi, 9 were still ongoing, 20 had PD and 19 restarted Axi (9 ongoing, 6 had further PD, 4 discontinued Axi again). Safety: 96.2% of pts had at least one adverse event (AE) and 40.5% had G3-G4 AEs with no treatment-related death. All-grades and G3-G4 axitinib-related AEs were reported in 34.2% and 11.4% of overall pts, respectively, and in 10.3% and 0% of those who discontinued Axi. Conclusions The TIDE-A study shows that TKI discontinuation is safe for selected mRCC pts with evidence of response to TKI+IO combos in first line. Axi discontinuation allows decreasing of toxicity, while maintaining the possibility of Axi benefit in case of its reintroduction.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
